We are live on ! Find out more
TTPH

Tetraphase Pharmaceuticals, Inc.
TTPH

Delisted

TTPH was delisted on the 28th of July, 2020.

91 hedge funds and large institutions have $72.6M invested in Tetraphase Pharmaceuticals, Inc. in 2016 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 34 increasing their positions, 24 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

42% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 24

16% more call options, than puts

Call options by funds: $164K | Put options by funds: $141K

1% more funds holding

Funds holding: 9091 (+1)

7% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 14

5% less capital invested

Capital invested by funds: $76.6M → $72.6M (-$4.02M)

Holders
91
Holders Change
+1
Holders Change %
+1.11%
% of All Funds
2.27%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
15
Increased
34
Reduced
24
Closed
14
Calls
$164K
Puts
$141K
Net Calls
+$23K
Net Calls Change
+$23K
Name Holding Trade Value Shares
Change
Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$9.37M +$98.9K +1,250 +1%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$7.93M -$633 -8 -0%
Canada Pension Plan Investment Board
3
Canada Pension Plan Investment Board
Ontario, Canada
$6.67M
Vanguard Group
4
Vanguard Group
Pennsylvania
$5.67M +$266K +3,359 +5%
BFA
5
BlackRock Fund Advisors
California
$4.92M -$1.2M -15,208 -20%
BIT
6
BlackRock Institutional Trust
California
$3.62M
Northern Trust
7
Northern Trust
Illinois
$3.36M +$10.5K +133 +0.3%
State Street
8
State Street
Massachusetts
$2.86M +$45K +569 +2%
RSCM
9
Rock Springs Capital Management
Maryland
$2.81M +$140K +1,775 +5%
EAM
10
Eventide Asset Management
Massachusetts
$2.42M
CS
11
Candriam SCA
Luxembourg
$1.51M
Renaissance Technologies
12
Renaissance Technologies
New York
$1.43M -$1.48M -18,714 -51%
RPAM
13
Rhenman & Partners Asset Management
Sweden
$1.21M
BCM
14
Bridgeway Capital Management
Texas
$1.13M
Geode Capital Management
15
Geode Capital Management
Massachusetts
$1.08M +$28.5K +360 +3%
Deutsche Bank
16
Deutsche Bank
Germany
$1.04M -$355K -4,488 -26%
Dimensional Fund Advisors
17
Dimensional Fund Advisors
Texas
$912K +$763K +9,648 +580%
California Public Employees Retirement System
18
California Public Employees Retirement System
California
$906K -$45.5K -575 -5%
TCM
19
Tekla Capital Management
Massachusetts
$775K
Acadian Asset Management
20
Acadian Asset Management
Massachusetts
$734K +$558K +7,059 +346%
Bank of New York Mellon
21
Bank of New York Mellon
New York
$732K +$132K +1,671 +23%
NI
22
Numeric Investors
Massachusetts
$729K -$1.29M -16,292 -64%
D.E. Shaw & Co
23
D.E. Shaw & Co
New York
$661K -$113K -1,424 -15%
Millennium Management
24
Millennium Management
New York
$634K +$77.3K +977 +14%
Morgan Stanley
25
Morgan Stanley
New York
$603K +$388K +4,903 +190%

TTPH Hedge Fund Activity: Q4 2016 in Review

91 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Tetraphase Pharmaceuticals, Inc. (TTPH) for Q4 2016, worth a combined $72.6M — down 5.3% from $76.6M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new TTPH positions and 14 closed out — a net gain of 1 holder — while 34 added to existing stakes and 24 trimmed.

The largest buyer was Dimensional Fund Advisors, adding an estimated $763K. The largest seller was Armistice Capital, exiting entirely with an estimated $2.54M sold.

  • 91 institutional investors held Tetraphase Pharmaceuticals, Inc. (TTPH) as of Q4 2016, up from 90 in Q3 2016.
  • Funds reported $72.6M of Tetraphase Pharmaceuticals, Inc. stock for Q4 2016, down 5.3% quarter-over-quarter.
  • 15 funds opened new Tetraphase Pharmaceuticals, Inc. positions in Q4 2016 and 14 closed out, a net change of +1 holder.
  • The largest Tetraphase Pharmaceuticals, Inc. buyer in Q4 2016 was Dimensional Fund Advisors, an estimated $763K added.
  • The largest Tetraphase Pharmaceuticals, Inc. seller in Q4 2016 was Armistice Capital, an estimated $2.54M sold.

Based on aggregated 13F filings for Q4 2016.